Politics

  • Most Popular
  • Most Shared

REUTERS SHOWCASE

Hefty Fine

Hefty Fine

Tribunal orders fined cement firms to pay $109 million fee.  Full Article 

Share Sale

Share Sale

Tata Tele (Maharashtra) share sale cancelled.  Full Article | Related Story 

Tech Buzz

Tech Buzz

Google's wearable Glass gadget: cool or creepy?  Full Article 

Biggest Investors

Biggest Investors

China, India to be world's two biggest investors by 2030: World Bank.  Full Article 

ITC Results

ITC Results

ITC quarterly profit rises 19.5 pct, meets estimates.  Full Article 

Gold Market

Gold Market

Column - China, India demand not enough to save gold: Clyde Russell.  Full Article 

Chit Fund Scam

Chit Fund Scam

Fund scams target Indians beyond the reach of banks.  Full Article 

Foreign Inflows

Foreign Inflows

Foreign investors buy most Indian stocks in 3 months.  Full Article 

Buy, Sell or Hold?

Buy, Sell or Hold?

Confused while buying stocks? Get buy, sell or hold recommendations from VantageTrade.  Full Coverage 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage 

MARKET EYE-Indian shares edge higher; pharma stocks gain

Related Topics

Stocks

   

Mon Nov 5, 2012 9:55am IST

* The BSE index up 0.11 percent and the NSE index
 adds 0.13 percent.
* Indian stocks gain despite a fall in Asian shares on Monday
tracking a sell-off in global shares late last week, as
investors continued to shed risk ahead of the closely fought
U.S. presidential election and looked past strong U.S. jobs data
to fragile economic growth prospects worldwide.   
* Shares of Dr. Reddy's Laboratories gain 0.8 percent,
up for a sixth day. India's no. 2 drugmaker posted on Tuesday a
better-than-expected 32 percent rise in quarterly net profit.
 
* Cipla gains 1.8 percent ahead of its quarterly
earnings later in the day.
* Larsen & Toubro gains 0.5 percent on churning in
favour of large cap industrial stocks.

 (abhishek.vishnoi@thomsonreuters.com)
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.